Last reviewed · How we verify
NCT05195736
Predicting COVID-19 Patients' Clinical Outcomes Using ICU Mobility Scale and MRC Sum Score
trial in COVID-19 in 33 participants. Completed in 31 December 2021.
31 December 2021
Quick facts
| Lead sponsor | Taichung Veterans General Hospital |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 33 |
| Start date | 16 September 2021 |
| Primary completion | 31 December 2021 |
| Estimated completion | 31 December 2021 |
| Sites | 1 location across Taiwan |
Conditions studied
- COVID-19 — all drugs for COVID-19 →
Sponsor
Taichung Veterans General Hospital
Who can join
Eligibility, any sex, with COVID-19. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The investigators hypothesize that early mobility condition and muscle power may be the predictive factors for Coronavirus disease 2019(COVID-19) patients' activity prognosis and hospitalization days. To prove our hypothesis, the investigators proposed a retrospective cohort study to see if ICU mobility scale(ICUMS) and Medical Research Council Sum Score(MRCSS) can predicted the patients' Barthel index after discharge and hospitalization days.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Predictors of Basic Activity in Daily Living and Length of Hospitalization in Patients with COVID-19.
I TJ, Tsai YL, Cheng YY. · · 2022 · cited 2× · PMID 36011246 · DOI 10.3390/healthcare10081589
Verify or expand the search:
- PubMed search for NCT05195736
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for COVID-19
Currently open trials in the same condition.
- NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults · Phase 1 · active not recruiting
- NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age · Phase 3 · active not recruiting
- NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes · Phase 1 · recruiting
- NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults · Phase 2 · recruiting
- NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A · Phase 3 · active not recruiting
Other Taichung Veterans General Hospital trials
Trials by the same sponsor.
- NCT06858436 — SGLT2 Inhibitor Utilization Re-perfusion Therapy · Phase 4 · not yet recruiting
- NCT07453953 — A Comparison of Clinical Efficacy of Mytocel MSK With AMT and PRP Injections in Patients With Knee Osteoarthritis · EARLY_PHASE1 · not yet recruiting
- NCT07487636 — 4DryField PH and Head and Neck Operations. · NA · enrolling by invitation
- NCT07284017 — The Impact of Neuronavigation in rTMS for Hemiplegic Stroke Patients. · NA · not yet recruiting
- NCT07363876 — The Efficacy of Ultrasonication in Combination With Corticosteroid Intraarticular Injection for Arthritis · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05195736 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Taichung Veterans General Hospital
- Last refreshed: 3 February 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05195736.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing